Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ziprasidone Extension in Pediatric Bipolar I
NCT03768726Phase 3Terminated
- Sponsor
- Viatris
- Start
- Dec 2018
- Primary completion
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ziprasidone in bipolar I disorder, sponsored by Viatris. Primary endpoint: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs). Started Dec 2018; status: terminated.
02
Drugs
ziprasidone
03
Conditions
bipolar I disorder
Beyond the preview
Go deeper on NCT03768726.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03768726.